MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Dienogest

Search medical newsFind research, conditions and clinical updates
  • Home
  • Dienogest
Comparative Efficacy and Safety of Elagolix Versus Dienogest in Moderate-to-Severe Endometriosis Pain: Insights from a Phase III Multicentric Trial
Posted innews OB/GYN & Women's Health

Comparative Efficacy and Safety of Elagolix Versus Dienogest in Moderate-to-Severe Endometriosis Pain: Insights from a Phase III Multicentric Trial

Posted by By MedXY 10/06/2026
This phase III study demonstrates that elagolix is non-inferior to dienogest in reducing moderate-to-severe endometriosis pain, with comparable safety and tolerability profiles, supporting elagolix as a valuable treatment option.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Navigating the Ethical Crossroads of Prenatal Testing for Adult-Onset Genetic Conditions: The Case of Huntington Disease
  • Genetic Biomarkers Define Distinct Clinical Subgroups in Giant Cell Arteritis: Implications for Diagnosis and Personalized Management
  • Refining CLAD Surveillance: Integrating Alveolar Nitric Oxide for Enhanced Lung Transplant Monitoring
  • Distinct Cancer Risks in Morphea and Systemic Sclerosis: Insights from a Large Population-Based Cohort Study
  • Refining Lymphovenous Anastomosis: Intraoperative Factors Driving Improved Outcomes in Lymphedema Surgery
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top